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Sepsis is a common reason for empiric antibiotics among hospi-
talized patients. We found that the median duration of empiric 
antibiotics (interquartile range) was 6 (4–9) days among 1047 
survivivors with pathogen-negative sepsis. These findings sug-
gest that patients with pathogen-negative sepsis could represent 
an important opportunity for antimicrobial stewardship.
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Sepsis is the most common indication for treatment with em-
piric antibiotics among hospitalized patients [1, 2]. At the same 
time that sepsis makes up a greater proportion of the condi-
tions cared for within intensive care units (ICUs), the rates of 
antimicrobial resistance have increased [3]. Given the success 
of sepsis bundles to improve patient outcomes, the Surviving 
Sepsis Campaign Guidelines now recommend broad-spectrum 
antibiotics within 1 hour of presentation in all patients with 
suspected sepsis [4, 5]. Unfortunately, these recommendations 
fail to acknowledge the difficulties in establishing an accurate 
diagnosis of sepsis attributed to underlying infection, the ad-
verse effects of routine antimicrobial administration, whether 
broad-spectrum antibiotic therapy is necessary in all patients 
with presumed sepsis, and whether the administered antibiotic 
regimen is active against the offending pathogens [6, 7].
A recent study found that 89% of patients meeting study in-
clusion criteria for sepsis were pathogen-negative [8]. These 
same investigators showed that patients with pathogen-negative 
sepsis had only slightly shorter durations of postsepsis hospi-
talization, compared with pathogen-positive patients, during 
which empiric antibiotic therapy would presumably have been 
admninistered [8]. The large percentage of pathogen-negative 
patients with sepsis and recent calls to treat such patients 
within 1 hour of presentation suggest that more patients with 
pathogen-negative sepsis will receive empiric antibiotic therapy. 
Therefore, we performed a retrospective cohort study to better 
understand the potential opportunity for antimicrobial stew-
ardship among patients with pathogen-negative sepsis.
METHODS
This study was conducted at Barnes-Jewish Hospital, a 1250-
bed academic medical center located in St. Louis, Missouri. 
The study period was January 1, 2010, through December 31, 
2017. All consecutive hospitalized patients with sepsis during 
the study period were analyzed for eligibility. This study was 
approved by the Washington University School of Medicine 
Human Studies Committee.
Utilizing a retrospective cohort study design from a previ-
ously validated database, all patients age ≥18 with sepsis were 
identified. Patients were included only if they had interna-
tional classification of diseases (ICD)-9 (995.92 and 785.52) 
and ICD-10 (R65.20 and R65.21) codes indicative of severe 
sepsis or septic shock. Only the first episode of sepsis was evalu-
ated. Baseline characteristics included age, gender, race, Acute 
Physiology and Chronic Health Evaluation (APACHE) II scores 
(calculated based on clinical data present during the 24 hours 
after starting empiric antibiotics), Charlson Comorbidity Index, 
and medical comorbidities. The start time for empiric anti-
biotics relative to the diagnosis of sepsis was determined using 
the difference in calendar days from obtaining microbiologic 
cultures (blood, urine, respiratory, other sterile sites including 
viral cultures and/or viral polymerase chain reaction) to the 
start of empiric antibiotics for presumed sepsis. Total duration 
of empiric antibiotic therapy was assessed by counting calendar 
days of inpatient intravenous antibiotic therapy after clinical di-
agnosis of sepsis.
To be included in the study, patients had to receive empiric 
intravenous antibiotics targeting likely community-acquired or 
health care–acquired pathogens based on the treating physi-
cian's assessment. Identification of the site of infection as the 
source of sepsis was based on review of the medical record. 
When the site of infection was described as unknown or un-
documented in the medical record, it was recorded as such. 
Discharge on hospice was considered a mortality equivalent. 
All data were derived from the informatics database provided 
by the Center for Clinical Excellence, BJC HealthCare.
We compared antibiotic treatment duration between 
pathogen-negative survivors receiving ≤3 days, 4–7 days, and 
>7 days of antibiotics for presumed sepsis. Univariate analysis 
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was performed by chi-square or Fisher exact test where appro-
priate for categorical values. The Student t test, Mann-Whitney 
U test, or Kruskal-Wallis test was used where appropriate for 
continuous variables. Continuous variables were reported as 
means with standard deviations or medians with interquartile 
ranges. Categorical data were expressed as frequencies. A  P 
value of <.05 was considered significant. All tests were 2-tailed. 
All analyses were done using SPSS, version 24.
RESULTS
During the study period, 1486 consecutive pathogen-ngative pa-
tients with sepsis were identified, with 1047 survivors. Hospital 
mortality was 29.5% (439 nonsurvivors). Nonsurvivors had 
greater APACHE II scores (median [interquartile range {IQR}], 
20 [16–24] vs 14 [11–18]; P  <  .001), Charlson Comorbidity 
Index scores (median [IQR], 5 [3–7] vs 4 [2–6]; P < .001), and 
significantly lower total antibiotic days (median [IQR], 4 [2–7] 
vs 6 [4–9] days; P < .001) and hospital duration (median [IQR], 
6 [3–11] vs 8 [5–14] days; P < .001).
Among the 1047 pathogen-negative survivors, the dura-
tion of empiric antibiotic therapy had a wide range (median 
[IQR], 6 [4–9] days). Greater APACHE II scores and Charlson 
Comorbidity Index scores occurred with increasing duration 
of empiric therapy (Table 1). Patients receiving mechanical 
ventilation also received longer courses of empiric antibiotics. 
Ventilator days, ICU days, hospital length of stay, and discharge 
to a nursing facility were greater among patients receiving more 
prolonged empiric courses of antibiotics.
Specific sites of infection identified as the source of sepsis 
(pneumonia, urinary tract, enteric, joint space, and central 
nervous system) were associated with increasing duration of 
empiric antibiotics (Table 1). Conversely, unknown or undocu-
mented sites of infection correlated with shorter durations of 
Table 1.  Characteristics for Hospital Survivors With Pathogen-Negative Sepsis
Duration of Empiric Antibiotic Treatment
Characteristic ≤3 d (n = 219) 4–7 d (n = 454) >7 d (n = 374) P
Age, y 60.2 ± 17.7 61.1 ± 16.3 60.5 ± 14.8 .758
Male 95 (43.4) 226 (49.8) 158 (42.2) .070
Race     
 White 133 (60.7) 299 (65.9) 252 (67.4) .116
 Black 76 (34.7) 128 (28.2) 94 (25.1)  
 Other 10 (4.6) 27 (5.9) 28 (7.5)  
APACHE II 12 [8–16] 14 [11–17] 16 [12–20] <.001
Charlson Comorbidity Index 3 [1–6] 4 [2–6] 4 [2–6] .003
Days to empiric antibioticsa 2 [0–8] 0 [0–5] 0 [0–4.25] <.001
Mechanical ventilation 23 (10.5) 115 (25.3) 174 (46.5) <.001
Renal replacement therapy 7 (3.2) 9 (2.0) 17 (4.5) .110
Ventilator days 4 [3–5] 7 [6–9] 11 [15–22] <.001
ICU days 0 [0–2] 2 [0–4] 5 [2–10] <.001
Hospital LOS, d 0 [0–0] 0 [0–1] 0 [0–4] <.001
Discharge disposition     
 Home 106 (48.4) 185 (40.7) 93 (24.9) <.001
 Home health 40 (18.3) 120 (26.4) 103 (27.5)  
 SNF/LTAC 38 (17.4) 112 (24.7) 150 (40.1)  
 Other 8 (3.7) 10 (2.2) 10 (2.7)  
30-d readmission 3 (1.4) 18 (4.0) 19 (5.1) .074
Postantibiotic culturesb 54 (24.7) 149 (32.8) 130 (34.8) .032
ID diagnosis     
 Pneumonia 7 (3.2) 42 (9.3) 67 (17.9) <.001
 Urinary tract 76 (34.7) 175 (38.5) 194 (51.9) <.001
 Intraabdominal 6 (2.7) 21 (4.6) 25 (6.7) .093
 Enteric 5 (2.3) 47 (10.4) 101 (27.0) <.001
 Joint space 3 (1.4) 9 (2.0) 38 (10.2) <.001
 CNS 7 (3.2) 9 (2.0) 20 (5.3) .030
 Unknownc 130 (59.4) 212 (46.7) 98 (26.2) <.001
Data are expressed as number (percentage), mean ± SD, or median [interquartile range].
Abbreviations: APACHE II, acute physiology and chronic health evaluation; CNS, central nervous system; ICU, intensive care unit; ID, infectious disease; LOS, length of stay; LTAC, long-term 
acute care facility; SNF, skilled nursing facility.
aCalendar days from the time when microbiologic cultures were obtained.
bCulture specimens obtained following the start of empiric antibiotic therapy for sepsis.
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empiric antibiotic therapy (Table 1). Patients with a site of infec-
tion identified as the source of sepsis had similar rates of having 
appropriate blood cultures and/or other bodily fluid cultures 
obtained as part of their evaluation compared with patients 
with an unknown site of infection (94.2% vs 94.6%; P = .807). 
Figure 1 shows that the overall duration of antibiotic therapy 
was statistically greater among patients with a clinically sus-
pected site of infection compared with those with an unknown 
or undocumented site of infection (median [IQR], 7 [5–11] vs 5 
[3–7] days; P < .001). The urinary tract was the most commonly 
identified site of infection. The duration of antibiotic therapy 
was statistically greater among patients with a urinary tract site 
of infection compared with those with an unknown or undo-
cumented site of infection (median [IQR], 7 [4–11] vs 5 [3–7] 
days; P < .001).
DISCUSSION
Our data suggest that the duration of empiric antimicrobial 
therapy in pathogen-negative sepsis is related to patient severity 
of illness and documented site of infection. The complexity of 
antibiotic decision-making in critically ill patients is illustrated 
by a study of ICU-acquired pneumonia (ICUAP) [9]. Three 
hundred forty-three patients with ICUAP were prospectively 
enrolled, of whom 140 (41%) had no microbiological confir-
mation, 121 (35%) patients developed ICUAP with multidrug-
resistant organisms (MDROs), and 82 (24%) were non-MDROs. 
All 3 patient groups had similar baseline characteristics 
including previous antibiotic use and prior hospital admission. 
Initially appropriate antibiotic therapy (IAAT) was associated 
with better ICU survival, and an adjusted multivariate regres-
sion logistic analysis identified infection with MDROs as a risk 
factor for greater ICU mortality. However, antibiotic consump-
tion was greater in patients without microbiologic confirmation 
compared with those who were culture-positive.
We previously demonstrated that patients with pathogen-
negative health care–associated pneumonia (HCAP) had lower 
severity of illness, hospital mortality, and shorter durations of 
antibiotic therapy compared with pathogen-positive HCAP 
patients [10]. We also demonstrated that critically ill patients 
with pneumonia could safely have their antimicrobial therapy 
de-escalated based on microbiologic assessment [11]. However, a 
study employing a large administrative data set from the National 
Inpatient Sample (NIS) found that individuals with pathogen-
negative sepsis had a greater mortality compared with those with 
pathogen-positive sepsis [12]. The authors of this study proposed 
several possible explanations for the greater mortality among 
pathogen-negative patients, including the observed greater dis-
ease severity and delays in empiric antibiotic administration 
and/or antibiotic durations that were inadequate [12]. The latter 
possibilities were merely hypotheses unsupported by their data. 
However, it is important to note that among pathogen-positive 
patients who received IAAT covering the offending pathogens, 
the severity of sepsis has been shown to be the most important 
determinant of outcome [13]. These observations emphasize the 
importance of discerning the impact of host factors and disease 
severity on patient outcomes, which may not be modifiable by 
antimicrobial therapy.
 The deleterious effects of antibiotic use for pathogen-negative 
infections has been well described in a number of clinical set-
tings [6, 12]. Moreover, the overuse of antibiotics paves the way 
for development of multidrug-resistant bacteria. This was nicely 
illustrated in a recent study of critically ill adult patients who 
received antipseudomonal β-lactam antibiotics, demonstrating 
that each additional day of exposure to cefepime, meropenem, 
and piperacillin-tazobactam was associated with an increased 
risk of new resistance development [14]. These studies illustrate 
the potential harm of unnecessary antibiotic administration.
There are several limitations of our study. First, the data come 
from a single center and may not be representative of other hos-
pitals. Second, the retrospective nature of the study limits our 
ability to determine all potential indications for the prescribed 
empiric antibiotic therapy. Third, we did not determine whether 
antibiotic de-escalation occurred in our patients receiving em-
piric therapy. Lastly, we may have missed patients empirically 
treated for pathogen-negative sepsis who did not have clinical 
specimens obtained for microbiologic evaluation.
In summary, our data suggest that patients with pathogen-
negative sepsis may represent an important opportunity for 





























Figure 1.  Box plot distributions for the duration of empiric antibiotic therapy 
for pathogen-negative surviving patients with sepsis according to whether they had 
an identified site of infection as the source of sepsis or whether the site of infection 
was unknown or undocumented in the medical record. The lines within the boxes 
represent the median values, the boxes represent the 25th and 75th percentiles, 
and the whisker lines represent the 5th and 95th percentiles (P < .001 for the com-
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patients received some form of unnecessary therapy. Given 
the outcome benefits observed with the combined use of 
molecular rapid diagnostic testing and antimicrobial stew-
ardship programs, similar approaches in individuals with 
pathogen-negative sepsis should be considered regardless of 
their severity of illness [15]. Future studies of antimicrobial 
stewardship directed at patients with pathogen-negative sepsis 
and septic shock are needed to optimize the administration of 
antibiotic therapy.
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